Fibrocell Science Inc (NASDAQ:FCSC) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,083,658 shares, a growth of 43.3% from the October 31st total of 756,335 shares. Based on an average daily trading volume, of 116,142 shares, the short-interest ratio is currently 9.3 days. Approximately 11.9% of the company’s shares are sold short.
Shares of Fibrocell Science (FCSC) opened at $1.37 on Monday. Fibrocell Science has a 52 week low of $1.32 and a 52 week high of $4.64.
Several research firms have recently commented on FCSC. Zacks Investment Research raised Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. HC Wainwright set a $6.00 price objective on Fibrocell Science and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price objective (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. Finally, ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Fibrocell Science presently has a consensus rating of “Hold” and a consensus target price of $5.21.
TRADEMARK VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Sees Large Increase in Short Interest” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/04/fibrocell-science-inc-fcsc-sees-large-increase-in-short-interest.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.